BGM Pharmaceuticals

Burgundy Access is a specialized pharmaceutical and healthcare services company focused on improving access to innovative and life changing medicines. The company works closely with global pharmaceutical manufacturers to facilitate the registration, distribution, and commercialization of niche and specialty therapies in emerging markets. With deep expertise in regulatory affairs, market access, and supply chain management, Burgundy Access bridges the gap between cutting edge treatments and the patients who need them most, ensuring timely and compliant delivery across diverse healthcare systems.

Driven by a commitment to patient-centric care, Burgundy Access partners with healthcare providers, governments, and industry stakeholders to expand availability of advanced therapies in areas such as oncology, rare diseases, and chronic conditions. The company emphasizes ethical practices, quality assurance, and sustainable growth while tailoring its solutions to meet local market needs. Through strategic collaborations and a strong focus on innovation, Burgundy Access continues to play a vital role in enhancing healthcare outcomes and increasing access to essential medicines across underserved regions.

Oethmaan Biosims is a South African pharmaceutical company focused on delivering affordable, high quality medicines across both private and public healthcare sectors. As a fully black owned enterprise, the company operates across the pharmaceutical value chain, from product development and regulatory approval to distribution, ensuring consistent access to essential treatments. With strong emphasis on quality and compliance, its products are approved by regulatory authorities and supported by internationally certified manufacturing partners, enabling the company to provide safe and reliable medicines to patients and healthcare providers.

The company places particular focus on biosimilar and generic medicines, aiming to address the rising cost of treating chronic and life threatening conditions such as cancer. By leveraging its own intellectual property portfolio and expanding product pipeline, Oethmaan Biosims continues to grow its presence across South Africa and into broader African markets. Through strategic partnerships, ongoing product development, and a commitment to accessibility, the company strives to improve healthcare outcomes and make essential medicines more affordable for communities in emerging economies.

Specpharm is a pharmaceutical company in South Africa that focuses on the development, manufacturing, and distribution of specialised medicines. The company is known for its work in providing treatments for complex and chronic conditions, including areas such as oncology, immunology, and other specialised therapeutic fields. By prioritising high quality standards and regulatory compliance, Specpharm ensures that its products meet the safety and efficacy requirements set within the pharmaceutical industry.

In addition to its product portfolio, Specpharm works closely with healthcare professionals to support effective treatment outcomes and improve patient care. The company plays a role in increasing access to specialised medicines within both the private and public healthcare sectors in South Africa. Through its focus on innovation, quality, and accessibility, Specpharm contributes to addressing critical healthcare needs and supporting better health outcomes for patients across the country.